Advanced

Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer.

Jögi, Annika LU ; Brennan, Donal J; Rydén, Lisa LU ; Magnusson, Kristina; Fernö, Mårten LU ; Stål, Olle; Borgquist, Signe LU ; Uhlen, Mathias; Landberg, Göran LU and Påhlman, Sven LU , et al. (2009) In Modern Pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 22. p.1564-1574
Abstract
Single-strand RNA-binding proteins (RBPs) are involved in many aspects of RNA metabolism and in the regulation of gene transcription. The RBP RBM3 was recently suggested to be a proto-oncogene in colorectal cancer; however, such a role has not been corroborated by previous studies in the colon or other tumor types, and the prognostic implications of tumor-specific RBM3 expression remain unclear. Mono-specific antibodies against RBM3 were generated. Antibody specificity was confirmed using siRNA gene silencing, western blotting and immunohistochemistry on a panel of breast cancer cell lines. Using tissue microarrays and IHC, RBM3 protein expression was examined in 48 normal tissues and in 20 common cancers. Additional analysis in two... (More)
Single-strand RNA-binding proteins (RBPs) are involved in many aspects of RNA metabolism and in the regulation of gene transcription. The RBP RBM3 was recently suggested to be a proto-oncogene in colorectal cancer; however, such a role has not been corroborated by previous studies in the colon or other tumor types, and the prognostic implications of tumor-specific RBM3 expression remain unclear. Mono-specific antibodies against RBM3 were generated. Antibody specificity was confirmed using siRNA gene silencing, western blotting and immunohistochemistry on a panel of breast cancer cell lines. Using tissue microarrays and IHC, RBM3 protein expression was examined in 48 normal tissues and in 20 common cancers. Additional analysis in two independent breast cancer cohorts (n=1016) with long-term follow-up was also carried out. RBM3 was upregulated in cancer compared to normal tissues. The nuclear expression of RBM3 in breast cancer was associated with low grade (P<0.001), small tumors (P<0.001), estrogen receptor (ER) positivity (P<0.001) and Ki-67 negativity (P<0.001) in both the breast cancer cohorts. An increased nuclear expression of RBM3 was associated with a prolonged overall and recurrence-free survival. The prognostic value was particularly pronounced in hormone receptor-positive tumors and remained significant in multivariate interaction analysis after controlling for tamoxifen treatment (HR: 0.49, 95% CI: 0.30-0.79, P=0.004). These data strongly indicate that nuclear RBM3 is an independent favorable prognostic factor in breast cancer, and seems to have a specific role in ER-positive tumors.Modern Pathology advance online publication, 4 September 2009; doi:10.1038/modpathol.2009.124. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Modern Pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
volume
22
pages
1564 - 1574
publisher
Nature Publishing Group
external identifiers
  • wos:000272207200006
  • pmid:19734850
  • scopus:71149089765
ISSN
1530-0285
DOI
10.1038/modpathol.2009.124
project
CREATE Health
language
English
LU publication?
yes
id
43b63f91-1497-4ac1-bcc0-ef3ecfce233d (old id 1483665)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19734850?dopt=Abstract
date added to LUP
2009-10-07 09:00:22
date last changed
2017-08-27 05:53:51
@article{43b63f91-1497-4ac1-bcc0-ef3ecfce233d,
  abstract     = {Single-strand RNA-binding proteins (RBPs) are involved in many aspects of RNA metabolism and in the regulation of gene transcription. The RBP RBM3 was recently suggested to be a proto-oncogene in colorectal cancer; however, such a role has not been corroborated by previous studies in the colon or other tumor types, and the prognostic implications of tumor-specific RBM3 expression remain unclear. Mono-specific antibodies against RBM3 were generated. Antibody specificity was confirmed using siRNA gene silencing, western blotting and immunohistochemistry on a panel of breast cancer cell lines. Using tissue microarrays and IHC, RBM3 protein expression was examined in 48 normal tissues and in 20 common cancers. Additional analysis in two independent breast cancer cohorts (n=1016) with long-term follow-up was also carried out. RBM3 was upregulated in cancer compared to normal tissues. The nuclear expression of RBM3 in breast cancer was associated with low grade (P&lt;0.001), small tumors (P&lt;0.001), estrogen receptor (ER) positivity (P&lt;0.001) and Ki-67 negativity (P&lt;0.001) in both the breast cancer cohorts. An increased nuclear expression of RBM3 was associated with a prolonged overall and recurrence-free survival. The prognostic value was particularly pronounced in hormone receptor-positive tumors and remained significant in multivariate interaction analysis after controlling for tamoxifen treatment (HR: 0.49, 95% CI: 0.30-0.79, P=0.004). These data strongly indicate that nuclear RBM3 is an independent favorable prognostic factor in breast cancer, and seems to have a specific role in ER-positive tumors.Modern Pathology advance online publication, 4 September 2009; doi:10.1038/modpathol.2009.124.},
  author       = {Jögi, Annika and Brennan, Donal J and Rydén, Lisa and Magnusson, Kristina and Fernö, Mårten and Stål, Olle and Borgquist, Signe and Uhlen, Mathias and Landberg, Göran and Påhlman, Sven and Pontén, Fredrik and Jirström, Karin},
  issn         = {1530-0285},
  language     = {eng},
  pages        = {1564--1574},
  publisher    = {Nature Publishing Group},
  series       = {Modern Pathology : an official journal of the United States and Canadian Academy of Pathology, Inc},
  title        = {Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer.},
  url          = {http://dx.doi.org/10.1038/modpathol.2009.124},
  volume       = {22},
  year         = {2009},
}